The use of chemokine-releasing tissue engineering scaffolds in a model of inflammatory response-mediated melanoma cancer metastasis

Biomaterials

Volumn 33, Issue 3, 2012, Pages 876-885

  Ko, Cheng Yu ^a   Wu, Lanxiao ^a   Nair, Ashwin M ^a   Tsai, Yi Ting ^a   Lin, Victor K ^b   Tang, Liping ^a  

^a The University of Texas at Arlington   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Animal model; B16F10 melanoma cells; Cancer metastasis; Foreign body reactions; Inflammation; Mice

Indexed keywords

ANIMAL MODEL; CANCER METASTASIS; FOREIGN BODY REACTIONS; INFLAMMATION; MELANOMA CELLS; MICE;

CARDIOVASCULAR SYSTEM; CELLS; CYTOLOGY; DERMATOLOGY; DISEASES; MAMMALS; ONCOLOGY; PATHOLOGY; TISSUE;

SCAFFOLDS (BIOLOGY);

CHEMOKINE; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; ERYTHROPOIETIN; MICROSPHERE; NEUTRALIZING ANTIBODY; SECONDARY LYMPHOID TISSUE CHEMOKINE; STROMAL CELL DERIVED FACTOR 1ALPHA; TISSUE SCAFFOLD;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL MIGRATION; CELL STRAIN; CONTROLLED STUDY; INFLAMMATION; MELANOMA; MELANOMA CELL; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; TISSUE ENGINEERING;

ANIMALS; CELL LINE, TUMOR; CHEMOKINES; DISEASE MODELS, ANIMAL; FOREIGN-BODY REACTION; HUMANS; MELANOMA; MICE; NEOPLASM METASTASIS; TISSUE ENGINEERING; TISSUE SCAFFOLDS;

ANIMALIA; MUS;

EID: 81155134776     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2011.10.002     Document Type: Article

References (76)

1. Chambers A.F., Groom A.C., MacDonald I.C. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002, 2:563-572.
2. Fidler I.J. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 2003, 3:453-458.
3. Welch D.R. Technical considerations for studying cancer metastasis in vivo. Clin Exp Metastasis 1997, 15:272-306.
4. Gupta G.P., Perk J., Acharyya S., de Candia P., Mittal V., Todorova-Manova K., et al. ID genes mediate tumor reinitiation during breast cancer lung metastasis. Proc Natl Acad Sci U S A 2007, 104:19506-19511.
5. Yamamoto M., Kikuchi H., Ohta M., Kawabata T., Hiramatsu Y., Kondo K., et al. TSU68 prevents liver metastasis of colon cancer xenografts by modulating the premetastatic niche. Cancer Res 2008, 68:9754-9762.
6. Cespedes M.V., Casanova I., Parreno M., Mangues R. Mouse models in oncogenesis and cancer therapy. Clin Transl Oncol 2006, 8:318-329.
7. Talmadge J.E., Singh R.K., Fidler I.J., Raz A. Murine models to evaluate novel and conventional therapeutic strategies for cancer. Am J Pathol 2007, 170:793-804.
8. Khanna C., Hunter K. Modeling metastasis in vivo. Carcinogenesis 2005, 26:513-523.
9. Schwertfeger K.L., Xian W., Kaplan A.M., Burnett S.H., Cohen D.A., Rosen J.M. A critical role for the inflammatory response in a mouse model of preneoplastic progression. Cancer Res 2006, 66:5676-5685.
10. Taketo M.M., Edelmann W. Mouse models of colon cancer. Gastroenterology 2009, 136:780-798.
11. Marx J. Cancer research. Inflammation and cancer: the link grows stronger. Science 2004, 306:966-968.
12. Lu H., Ouyang W., Huang C. Inflammation, a key event in cancer development. Mol Cancer Res 2006, 4:221-233.
13. Lorusso G., Ruegg C. The tumor microenvironment and its contribution to tumor evolution toward metastasis. Histochem Cell Biol 2008, 130:1091-1103.
14. Pollard J.W. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004, 4:71-78.
15. Melnikova V.O., Bar-Eli M. Inflammation and melanoma metastasis. Pigment Cell Melanoma Res 2009, 22:257-267.
16. Aggarwal B.B., Shishodia S., Sandur S.K., Pandey M.K., Sethi G. Inflammation and cancer: how hot is the link?. Biochem Pharmacol 2006, 72:1605-1621.
17. Arias J.I., Aller M.A., Arias J. Cancer cell: using inflammation to invade the host. Mol Cancer 2007, 6:29.
18. Ben-Baruch A. The multifaceted roles of chemokines in malignancy. Cancer Metastasis Rev 2006, 25:357-371.
19. Gomperts B.N., Strieter R.M. Chemokine-directed metastasis. Contrib Microbiol 2006, 13:170-190.
20. Kakinuma T., Hwang S.T. Chemokines, chemokine receptors, and cancer metastasis. J Leukoc Biol 2006, 79:639-651.
21. Shields J.D., Emmett M.S., Dunn D.B., Joory K.D., Sage L.M., Rigby H., et al. Chemokine-mediated migration of melanoma cells towards lymphatics-a mechanism contributing to metastasis. Oncogene 2007, 26:2997-3005.
22. Soria G., Ben-Baruch A. The inflammatory chemokines CCL2 and CCL5 in breast cancer. Cancer Lett 2008, 267:271-285.
23. Germano G., Allavena P., Mantovani A. Cytokines as a key component of cancer-related inflammation. Cytokine 2008, 43:374-379.
24. Luboshits G., Shina S., Kaplan O., Engelberg S., Nass D., Lifshitz-Mercer B., et al. Elevated expression of the CC chemokine regulated on activation, normal T cell expressed and secreted (RANTES) in advanced breast carcinoma. Cancer Res 1999, 59:4681-4687.
25. Muller A., Homey B., Soto H., Ge N., Catron D., Buchanan M.E., et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001, 410:50-56.
26. Murakami T., Maki W., Cardones A.R., Fang H., Tun Kyi A., Nestle F.O., et al. Expression of CXC chemokine receptor-4 enhances the pulmonary metastatic potential of murine B16 melanoma cells. Cancer Res 2002, 62:7328-7334.
27. Ghadjar P., Coupland S.E., Na I.K., Noutsias M., Letsch A., Stroux A., et al. Chemokine receptor CCR6 expression level and liver metastases in colorectal cancer. J Clin Oncol 2006, 24:1910-1916.
28. Ghadjar P., Rubie C., Aebersold D.M., Keilholz U. The chemokine CCL20 and its receptor CCR6 in human malignancy with focus on colorectal cancer. Int J Cancer 2009, 125:741-745.
29. Bussard K.M., Gay C.V., Mastro A.M. The bone microenvironment in metastasis; what is special about bone?. Cancer Metastasis Rev 2008, 27:41-55.
30. Kamath S., Bhattacharyya D., Padukudru C., Timmons R.B., Tang L. Surface chemistry influences implant-mediated host tissue responses. J Biomed Mater Res A 2008, 86:617-626.
31. Nair A., Zou L., Bhattacharyya D., Timmons R.B., Tang L. Species and density of implant surface chemistry affect the extent of foreign body reactions. Langmuir 2008, 24:2015-2024.
32. Weng H., Zhou J., Tang L., Hu Z. Tissue responses to thermally-responsive hydrogel nanoparticles. J Biomater Sci Polym Ed 2004, 15:1167-1180.
33. Carvalho M.A., Zecchin K.G., Seguin F., Bastos D.C., Agostini M., Rangel A.L., et al. Fatty acid synthase inhibition with Orlistat promotes apoptosis and reduces cell growth and lymph node metastasis in a mouse melanoma model. Int J Cancer 2008, 123:2557-2565.
34. Gerber S.A., Rybalko V.Y., Bigelow C.E., Lugade A.A., Foster T.H., Frelinger J.G., et al. Preferential attachment of peritoneal tumor metastases to omental immune aggregates and possible role of a unique vascular microenvironment in metastatic survival and growth. Am J Pathol 2006, 169:1739-1752.
35. Hippo Y., Yashiro M., Ishii M., Taniguchi H., Tsutsumi S., Hirakawa K., et al. Differential gene expression profiles of scirrhous gastric cancer cells with high metastatic potential to peritoneum or lymph nodes. Cancer Res 2001, 61:889-895.
36. Nair A., Shen J., Lotfi P., Ko C.Y., Zhang C.C., Tang L. Biomaterial implants mediate autologous stem cell recruitment in mice. Acta Biomater 2011, 7:3887-3895.
37. Thevenot P.T., Nair A.M., Shen J., Lotfi P., Ko C.Y., Tang L. The effect of incorporation of SDF-1alpha into PLGA scaffolds on stem cell recruitment and the inflammatory response. Biomaterials 2010, 31:3997-4008.
38. Fessi H., Puisieux F., Devissaguet J.P., Ammoury N., Benita S. Nanocapsules formation by interfacial polymer deposition following solvent displacement. Int J Pharm 1989, 55:R1-R4.
39. Nair A., Thevenot P., Dey J., Shen J., Sun M.W., Yang J., et al. Novel polymeric scaffolds using protein microbubbles as porogen and growth factor carriers. Tissue Eng Part C Methods 2010, 16:23-32.
40. Ikebe M., Kitaura Y., Nakamura M., Tanaka H., Yamasaki A., Nagai S., et al. Lipopolysaccharide (LPS) increases the invasive ability of pancreatic cancer cells through the TLR4/MyD88 signaling pathway. J Surg Oncol 2009, 100:725-731.
41. Koller F.L., Hwang D.G., Dozier E.A., Fingleton B. Epithelial interleukin-4 receptor expression promotes colon tumor growth. Carcinogenesis 2010, 31:1010-1017.
42. Longo-Imedio M.I., Longo N., Trevino I., Lazaro P., Sanchez-Mateos P. Clinical significance of CXCR3 and CXCR4 expression in primary melanoma. Int J Cancer 2005, 117:861-865.
43. Folkman J. The role of angiogenesis in tumor growth. Semin Cancer Biol 1992, 3:65-71.
44. Nguyen D.X., Bos P.D., Massague J. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 2009, 9:274-284.
45. Craig M.J., Loberg R.D. CCL2 (Monocyte Chemoattractant Protein-1) in cancer bone metastases. Cancer Metastasis Rev 2006, 25:611-619.
46. Lee S.S., Morgenstern L., Phillips E.H., Hiatt J.R., Margulies D.R. Splenectomy for splenic metastases: a changing clinical spectrum. Am Surg 2000, 66:837-840.
47. Lin E.Y., Nguyen A.V., Russell R.G., Pollard J.W. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med 2001, 193:727-740.
48. Mochizuki Y., Nakanishi H., Kodera Y., Ito S., Yamamura Y., Kato T., et al. TNF-alpha promotes progression of peritoneal metastasis as demonstrated using a green fluorescence protein (GFP)-tagged human gastric cancer cell line. Clin Exp Metastasis 2004, 21:39-47.
49. Tang L., Jennings T.A., Eaton J.W. Mast cells mediate acute inflammatory responses to implanted biomaterials. Proc Natl Acad Sci U S A 1998, 95:8841-8846.
50. Tang L., Lucas A.H., Eaton J.W. Inflammatory responses to implanted polymeric biomaterials: role of surface-adsorbed immunoglobulin G. J Lab Clin Med 1993, 122:292-300.
51. Zdolsek J., Eaton J.W., Tang L. Histamine release and fibrinogen adsorption mediate acute inflammatory responses to biomaterial implants in humans. J Transl Med 2007, 5:31.
52. Tang L., Eaton J.W. Inflammatory responses to biomaterials. Am J Clin Pathol 1995, 103:466-471.
53. Tang L., Eaton J.W. Natural responses to unnatural materials: a molecular mechanism for foreign body reactions. Mol Med 1999, 5:351-358.
54. Tang L., Hu W. Molecular determinants of biocompatibility. Expert Rev Med Devices 2005, 2:493-500.
55. Pathi S.P., Lin D.D., Dorvee J.R., Estroff L.A., Fischbach C. Hydroxyapatite nanoparticle-containing scaffolds for the study of breast cancer bone metastasis. Biomaterials 2011, 32:5112-5122.
56. Moreau J.E., Anderson K., Mauney J.R., Nguyen T., Kaplan D.L., Rosenblatt M. Tissue-engineered bone serves as a target for metastasis of human breast cancer in a mouse model. Cancer Res 2007, 67:10304-10308.
57. Bhardwaj U., Sura R., Papadimitrakopoulos F., Burgess D.J. Controlling acute inflammation with fast releasing dexamethasone-PLGA microsphere/pva hydrogel composites for implantable devices. J Diabetes Sci Technol 2007, 1:8-17.
58. Patil S.D., Papadmitrakopoulos F., Burgess D.J. Concurrent delivery of dexamethasone and VEGF for localized inflammation control and angiogenesis. J Control Release 2007, 117:68-79.
59. Zolnik B.S., Burgess D.J. Evaluation of in vivo-in vitro release of dexamethasone from PLGA microspheres. J Control Release 2008, 127:137-145.
60. Pugliese M.S., Beatty J.D., Tickman R.J., Allison K.H., Atwood M.K., Szymonifka J., et al. Impact and outcomes of routine microstaging of sentinel lymph nodes in breast cancer: significance of the pN0(i+) and pN1mi categories. Ann Surg Oncol 2009, 16:113-120.
61. Tachibana T., Yoshida K. Role of the regional lymph node in cancer metastasis. Cancer Metastasis Rev 1986, 5:55-66.
62. Steeg P.S. Tumor metastasis: mechanistic insights and clinical challenges. Nat Med 2006, 12:895-904.
63. Balch C.M., Soong S.J., Gershenwald J.E., Thompson J.F., Reintgen D.S., Cascinelli N., et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American joint committee on cancer melanoma staging system. J Clin Oncol 2001, 19:3622-3634.
64. Darling G. The role of lymphadenectomy in esophageal cancer. J Surg Oncol 2009, 99:189-193.
65. Das S., Skobe M. Lymphatic vessel activation in cancer. Ann N Y Acad Sci 2008, 1131:235-241.
66. Uharcek P. Prognostic factors in endometrial carcinoma. J Obstet Gynaecol Res 2008, 34:776-783.
67. Maekawa S., Iwasaki A., Shirakusa T., Kawakami T., Yanagisawa J., Tanaka T., et al. Association between the expression of chemokine receptors CCR7 and CXCR3, and lymph node metastatic potential in lung adenocarcinoma. Oncol Rep 2008, 19:1461-1468.
68. Wiley H.E., Gonzalez E.B., Maki W., Wu M.T., Hwang S.T. Expression of CC chemokine receptor-7 and regional lymph node metastasis of B16 murine melanoma. J Natl Cancer Inst 2001, 93:1638-1643.
69. Mirmohammadsadegh A., Marini A., Gustrau A., Delia D., Nambiar S., Hassan M., et al. Role of erythropoietin receptor expression in malignant melanoma. J Invest Dermatol 2010, 130:201-210.
70. Lee A.S., Kim D.H., Lee J.E., Jung Y.J., Kang K.P., Lee S., et al. Erythropoietin induces lymph node lymphangiogenesis and lymph node tumor metastasis. Cancer Res 2011, 71:4506-4517.
71. Arcasoy M.O., Jiang X., Haroon Z.A. Expression of erythropoietin receptor splice variants in human cancer. Biochem Biophys Res Commun 2003, 307:999-1007.
72. Henke M., Laszig R., Rube C., Schafer U., Haase K.D., Schilcher B., et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003, 362:1255-1260.
73. Lappin T.R., Maxwell A.P., Johnston P.G. EPO's alter ego: erythropoietin has multiple actions. Stem Cells 2002, 20:485-492.
74. Weiss M.J. New insights into erythropoietin and epoetin alfa: mechanisms of action, target tissues, and clinical applications. Oncologist 2003, 8(Suppl.3):18-29.
75. Katz O., Gil L., Lifshitz L., Prutchi-Sagiv S., Gassmann M., Mittelman M., et al. Erythropoietin enhances immune responses in mice. Eur J Immunol 2007, 37:1584-1593.
76. Yuan R., Maeda Y., Li W., Lu W., Cook S., Dowling P. Erythropoietin: a potent inducer of peripheral immuno/inflammatory modulation in autoimmune EAE. PLoS One 2008, 3. e1924.